COVA322: Phase Ib/IIa started

Covagen began a double-blind, placebo-controlled, German Phase Ib/IIa trial to evaluate single ascending-doses of COVA322 in about 39 patients with psoriasis. COVA322 was developed using Covagen's Fyn...